Abstract
Respiratory syncytial virus (RSV) is one of the main seasonal respiratory pathogens in the United States and causes up to 240,000 hospitalizations per year among children under five and adults over 60. RSV is classified into two subtypes, RSV-A and RSV-B. Although several RSV vaccines and a preventative monoclonal antibody, nirsevimab, were recently approved by the FDA, vaccination and prevention measures remain low even among age groups at higher risk for hospitalization. To better understand the epidemiology of RSV, we analyzed RSV-positive nasopharyngeal swabs from Boston Medical Center and its satellite clinics from January to June 2024 using amplicon-based whole-genome sequencing. Of the 59 samples collected, 19 were from children under five years of age, and 17 were from adults over the age of 60. Fifty-four samples sequenced successfully, with over 90% of the genome at a minimum of 20-fold coverage.
We found that over 80% of the samples were RSV-B; 48 RSV-B samples and 6 RSV-A samples. This represents a major switch from 2022, when Boston RSV samples were ~90% RSV-A. 45 of 48 RSV-B samples mapped into a single clade (B.D.E.1). These samples do not cluster to a single source within the B.D.E.1 clade, suggesting that the predominance of RSV-B is multifactorial, not the selective expansion of a single variant. We also found examples of identical/highly related genomes among our samples, suggesting clustered transmission. One infant had documented nirsevimab therapy forty days prior to RSV isolation. None of the adults had documented RSV vaccination, and mutations associated with nirsevimab resistance or vaccine escape were not observed. Our work highlights the importance of genomic surveillance for respiratory pathogens as a means to monitor transmission dynamics, such as the unexpected switch from RSV-A to RSV-B subtype dominance, to identify examples of superspreading events, and to understand the epidemiological changes that may be associated with nirsevimab and RSV vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Sample and data collection was funded by the Massachusetts Consortium for Pathogen Readiness (Mass-CPR). This publication was supported by the Office of Advanced Molecular Detection, Centers for Disease Control and Prevention through Cooperative Agreement Number CK22-2204. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All sample and data collection was approved by the Boston University institutional review board (H-42887).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Sharing Statement
Raw sequencing data is available from the Sequencing Read Archive (SRA), within BioProject PRJNA1223358. Genome consensus sequences are available from GISAID (accession numbers EPI_ISL_19725019 to EPI_ISL_19725072). Code used for analysis can be found at github.com/neidl-connor-lab/rsv-2024.
